Laboratory of Experimental Endocrinology, Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Pedro de Toledo 669, Vila Clementino, São Paulo, SP, 04039-032, Brazil.
Laboratory of Experimental Endocrinology, Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Pedro de Toledo 669, Vila Clementino, São Paulo, SP, 04039-032, Brazil.
Mol Cell Endocrinol. 2019 Mar 1;483:11-23. doi: 10.1016/j.mce.2018.12.015. Epub 2019 Jan 17.
The aim of the present study was to investigate the subcellular localization of estrogen receptors ERα and ERβ in androgen-independent prostate cancer cell line DU-145, and the possible role of exportin CRM1 on ERs distribution. In addition, we evaluated the ERs contribution to activation of ERK1/2 and AKT. Immunostaining of ERα and ERβ was predominantly found in the extranuclear regions of DU-145 cells. CRM1 inhibitor Leptomycin B reduced drastically the presence of ERα and ERβ in the extranuclear regions and increased in the nuclei, indicating the possible involvement of CRM1 on ERs nuclear-cytoplasmic shuttling. 17β-estradiol (E2), ERα-selective agonist PPT and ERβ-selective agonist DPN induced a rapid increase on ERK1/2 phosphorylation. E2-induced ERK1/2 activation was partially inhibited when cells were pretreated with ERα- or ERβ-selective antagonists, and blocked by simultaneous pretreatment with both antagonists, suggesting ERα/β heterodimers formation. Furthermore, E2 treatment did not activate AKT pathway. Therefore, we highlighted a possible crosstalk between extranuclear and nuclear ERs and their upstream and downstream signaling molecules as an important mechanism to control ER function as a potential therapeutic target in prostate cancer cells.
本研究旨在探讨雌激素受体 ERα 和 ERβ 在雄激素非依赖性前列腺癌细胞系 DU-145 中的亚细胞定位,以及出口蛋白 CRM1 对 ERs 分布的可能作用。此外,我们评估了 ERs 对 ERK1/2 和 AKT 激活的贡献。免疫染色显示 ERα 和 ERβ 主要存在于 DU-145 细胞的核外区域。CRM1 抑制剂 Leptomycin B 大大减少了 ERα 和 ERβ 在核外区域的存在,并增加了在核内的存在,表明 CRM1 可能参与 ERs 的核质穿梭。17β-雌二醇(E2)、ERα 选择性激动剂 PPT 和 ERβ 选择性激动剂 DPN 诱导 ERK1/2 磷酸化的快速增加。当细胞用 ERα 或 ERβ 选择性拮抗剂预先处理时,E2 诱导的 ERK1/2 激活被部分抑制,并且同时用两种拮抗剂预处理被阻断,表明 ERα/β 异二聚体的形成。此外,E2 处理不会激活 AKT 途径。因此,我们强调了核外和核内 ERs 及其上游和下游信号分子之间的可能串扰作为控制 ER 功能的重要机制,作为前列腺癌细胞中潜在的治疗靶点。